Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday

Processa Pharmaceuticals (NASDAQ:PCSA) will likely be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect Processa Pharmaceuticals to post earnings of ($0.92) per share for the quarter.

Processa Pharmaceuticals (NASDAQ:PCSA) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.18. On average, analysts expect Processa Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Processa Pharmaceuticals Stock Up 11.4 %

NASDAQ PCSA opened at $0.41 on Wednesday. The business’s fifty day simple moving average is $0.53 and its 200-day simple moving average is $0.91. Processa Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $3.31. The firm has a market cap of $2.17 million, a PE ratio of -0.12 and a beta of 0.75.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Processa Pharmaceuticals in a research report on Thursday, December 5th.

Insider Buying and Selling at Processa Pharmaceuticals

In related news, insider David Young bought 124,500 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was purchased at an average cost of $0.80 per share, with a total value of $99,600.00. Following the purchase, the insider now directly owns 205,405 shares of the company’s stock, valued at $164,324. This trade represents a 153.88 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO George K. Ng acquired 87,200 shares of the stock in a transaction dated Monday, January 27th. The shares were bought at an average cost of $0.80 per share, with a total value of $69,760.00. Following the completion of the transaction, the chief executive officer now owns 87,200 shares of the company’s stock, valued at approximately $69,760. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 224,100 shares of company stock valued at $179,280 over the last quarter. 13.00% of the stock is owned by company insiders.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.